Safety assessment of prucalopride in elderly patients with constipation: A double-blind, placebo-controlled study

M. Camilleri, G. Beyens, R. Kerstens, P. Robinson, L. Vandeplassche

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

Chronic constipation is common among nursing home residents. The aim of this study was to evaluate safety, tolerability and pharmacokinetics of the selective 5HT4 receptor agonist prucalopride in elderly, chronically constipated patients in nursing homes. A multicentre, phase II, randomized, double-blind dose-escalation study in 89 elderly constipated nursing home residents treated with placebo, 0.5, 1 or 2 mg prucalopride once daily for 28 days was analysed. Adverse events, vital signs, ECG, Holter monitor and pharmacokinetics were assessed (Clinicaltrials.gov identifier: NCT00627692). Patients' mean age was 83 years; 88% had a history of cardiovascular diseases. Most frequent adverse events, at least possibly related to prucalopride, were diarrhoea and abdominal pain. Relative to placebo, there were no differences in vital signs, ECG corrected QT interval, ECG morphology parameters, or incidence of supraventricular or ventricular arrhythmias on Holter monitoring. Plasma prucalopride concentrations increased proportionally with administered dose. Prucalopride up to 2 mg once daily for 4 weeks was safe and well-tolerated by constipated elderly patients, with no differences vs placebo in ECG or a range of Holter-monitoring parameters.

Original languageEnglish (US)
Pages (from-to)1256-1263+e117
JournalNeurogastroenterology and Motility
Volume21
Issue number12
DOIs
StatePublished - Dec 1 2009

Keywords

  • Arrhythmia
  • Cardiac
  • Corrected QT interval
  • Safety
  • Satisfaction

ASJC Scopus subject areas

  • Physiology
  • Endocrine and Autonomic Systems
  • Gastroenterology

Fingerprint Dive into the research topics of 'Safety assessment of prucalopride in elderly patients with constipation: A double-blind, placebo-controlled study'. Together they form a unique fingerprint.

  • Cite this